Enhancing therapeutic efficacy in breast cancer: a study on the combined cytotoxic effects of doxorubicin and MPC-3100

Doxorubicin-loaded mPEG-pPAd-mPEG triblock polymeric nanoparticles for drug delivery systems: Preparation and in vitro evaluation

(2023) Nazan Gökşen Tosun et al.   Journal of Molecular Structure

Current and future burden of breast cancer: Global statistics for 2020 and 2040

(2022) Melina Arnold et al.   BREAST

Therapeutic Effects of Conditioned Medium of Neural Differentiated Human Bone Marrow-Derived Stem Cells on Rotenone-Induced Alpha-Synuclein Aggregation and Apoptosis

(2021) Mahesh Ramalingam et al.   Stem Cells International

Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines

(2021) Aykut Özgür et al.   MOLECULAR BIOLOGY REPORTS

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells

(2021) Min Ye et al.   Frontiers in Pharmacology

Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy

(2021) Muhammad Sohail et al.   Expert Review of Anticancer Therapy

Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems

(2020) Patrícia de Faria Lainetti et al.   Pharmaceutics

Combination therapies with HSP90 inhibitors against colorectal cancer

(2019) Kushtrim Kryeziu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Targeting Hsp70: A possible therapy for cancer

(2016) Sanjay Kumar et al.   CANCER LETTERS

In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines

(2016) Tarik Ghadban et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer

(2015) Alba Dalmases et al.   Oncotarget

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes

(2013) Julie C. Friedland et al.   INVESTIGATIONAL NEW DRUGS

Geldanamycin and its derivatives as Hsp90 inhibitors

(2012) Magdalena Gorska   Frontiers in Bioscience-Landmark

Discovery of (2S)-1-[4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a Purine-Based Hsp90 Inhibitor

(2012) Se-Ho Kim et al.   JOURNAL OF MEDICINAL CHEMISTRY

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

(2011) S. Modi et al.   CLINICAL CANCER RESEARCH

Chaperone-dependent stabilization and degradation of p53 mutants

(2008) P Muller et al.   ONCOGENE